RxDoctor Payments Data

Brian Kline, MD

Family Medicine · Fayetteville, NYNPI 1689965303

Payments from drug & device makers

$620in general payments, 2019–2025

Across 29 payments — averaging $21.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$205
  • Welch Allyn$100
  • Novo Nordisk$95
  • Lilly USA, LLC$56
  • Amgen$50
  • Pfizer$37
  • plus $77 from 3 others

What the payments were for

  • Speaking & faculty fees$10016%
  • Food & beverage$52084%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$620 in reported general payments places this provider in the 55th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$120,548
Medicare patients
327
Services billed
1,862

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin92$83,277
EliquisApixaban65$45,958
OzempicSemaglutide29$44,287
RybelsusSemaglutide31$37,370
JanuviaSitagliptin Phosphate32$23,849
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$23,402
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$21,677
XareltoRivaroxaban25$17,393
FarxigaDapagliflozin Propanediol12$14,514
Spiriva HandihalerTiotropium Bromide14$7,638
SymbicortBudesonide/Formoterol Fumarate25$6,177
Albuterol Sulfate HfaAlbuterol Sulfate130$3,551
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,726
Atorvastatin Calcium254$2,145
Levothyroxine Sodium133$1,868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$26$83,27792 claims
Novo NordiskOzempic, Rybelsus$95$81,65760 claims
PfizerEliquis$37$45,95865 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$205$42,36762 claims
GSKTrelegy Ellipta$15$23,40225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,321 family medicine providers in New York.

Other family medicine in Fayetteville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →